Abstract
Aim. To study the efficacy of ivabradine in the prevention of cardiotoxic effects due to chemotherapeutic drugs in patients with breast cancer. Material and methods. The open randomized uncontrolled study included 55 patients with breast cancer who had to undergo chemotherapy by anthracyclines. The inclusion criterion was a heart rate >70 beats/min. Collection of complaints and anamnesis, ECG, echocardiography, routine laboratory tests were performed in all patients initially and after 1, 3, 6 and 12 months. All patients were treated with polychemotherapy with anthracyclines in combination with cyclophosphamide and fluorouracil. The patients included into the study were randomized into two groups. Patients of the main group (n=23) were additionally prescribed ivabradine in a daily dose of 10 mg followed by a dose titration. Patients of the control group (n=32) received only polychemotherapy. Results. In the main group a decrease in heart rate was observed already by the first month (from 83.6±9.5 to 67.1±7.5 beats/min, p 0.05). A significant change in the LV ejection fraction was not found in both groups. Significant differences in LV global longitudinal strain were found between groups in 1, 3 and 6 months of observation (p 70 beats/min was safe and did not cause bradycardia. Ivabradine use was accompanied by a significant reduction in a number of patients with complaints of palpitation, contributed to the preservation of normalLV global longitudinal deformation in chemotherapy, while the control group had negative changes with a maximum by the 6th month of follow-up.
Highlights
Possibilities of Ivabradine, a Selective Inhibitor of Ion f-Channels of Sinus Node, in Prevention of Anthracycline Cardiotoxicity in Patients with Breast Cancer Yury A
Ivabradine use was accompanied by a significant reduction in a number of patients with complaints of palpitation, contributed to the preservation of normal left ventricle (LV) global longitudinal deformation in chemotherapy, while the control group had negative changes with a maximum by the 6th month of follow-up
Терапия ивабрадином на фоне химиотерапевтического лечения была безопасной, она предотвращала снижение глобальной продольной систолической деформации левого желудочка
Summary
Возможности селективного ингибитора ионных f-каналов синусового узла ивабрадина в профилактике антрациклиновой кардиотоксичности у больных раком молочной железы. Possibilities of Ivabradine, a Selective Inhibitor of Ion f-Channels of Sinus Node, in Prevention of Anthracycline Cardiotoxicity in Patients with Breast Cancer Yury A. Ivabradine use was accompanied by a significant reduction in a number of patients with complaints of palpitation, contributed to the preservation of normal LV global longitudinal deformation in chemotherapy, while the control group had negative changes with a maximum by the 6th month of follow-up.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have